CLINICAL TRIALS

PERFORMA TRIAL: Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects with MASH

STATUS: Active

The purpose of the study is to assess the effects of pemvidutide on MASH resolution and MASH fibrosis.

PERFORMA Phase 3 MASH Study Protocol

PERFORMA Phase 3 MASH Study Protocol

If you are interested in enrolling in the clinical trial or would like more information, please click here to contact us.

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects with Metabolic dysfunction-associated steatohepatitis (MASH)

STATUS: Completed

For more information

The purpose of the study was to assess the effects of pemvidutide on MASH resolution and MASH fibrosis.

For details on the IMPACT Phase 2b MASH trial results, click here.

RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects with Obesity or Overweight

STATUS: Active

For more information

The purpose of the study is to assess the effects of pemvidutide on alcohol consumption and body weight. Enrollment completed in November 2025. For details of the RECLAIM Phase 2 AUD trial results, click here.

RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

STATUS: Active

For more information

The purpose of the study is to assess the effects of pemvidutide on liver disease due to excess alcohol consumption. Enrollment is complete, with topline data expected in the second half of 2027.